Free Trial

Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals logo
$32.09 +0.64 (+2.03%)
As of 04:00 PM Eastern

SUPN vs. JAZZ, PRGO, PCRX, NKTR, OMER, ASMB, CPIX, LLY, JNJ, and ABBV

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry.

Supernus Pharmaceuticals vs. Its Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Jazz Pharmaceuticals presently has a consensus price target of $184.00, indicating a potential upside of 68.61%. Supernus Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 12.18%. Given Jazz Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92
Supernus Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Jazz Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.91 beat Jazz Pharmaceuticals' score of 0.69 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Supernus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 11.86% compared to Supernus Pharmaceuticals' net margin of 9.27%. Jazz Pharmaceuticals' return on equity of 26.62% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals11.86% 26.62% 9.14%
Supernus Pharmaceuticals 9.27%12.23%9.17%

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.06B1.62$560.12M$7.5014.55
Supernus Pharmaceuticals$661.82M2.71$73.86M$1.1128.91

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

MetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.80B$3.86B$5.46B$8.92B
Dividend YieldN/A1.16%5.24%4.04%
P/E Ratio28.916.6127.0120.12
Price / Sales2.7110.77380.1493.34
Price / Cash7.676.5826.2128.59
Price / Book1.712.657.995.57
Net Income$73.86M-$109.62M$3.16B$248.40M
7 Day Performance0.85%0.36%3.69%6.04%
1 Month Performance-3.20%3.56%2.90%7.69%
1 Year Performance22.29%26.13%34.30%20.97%

Supernus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
2.8598 of 5 stars
$32.09
+2.0%
$36.00
+12.2%
+20.8%$1.80B$661.82M28.91580High Trading Volume
JAZZ
Jazz Pharmaceuticals
4.8941 of 5 stars
$107.60
-1.7%
$184.00
+71.0%
+6.3%$6.62B$4.06B14.352,800
PRGO
Perrigo
4.8428 of 5 stars
$26.74
-1.7%
$33.00
+23.4%
+5.1%$3.74B$4.37B-20.418,379Analyst Upgrade
PCRX
Pacira BioSciences
3.4244 of 5 stars
$23.22
flat
$26.44
+13.9%
+10.3%$1.07B$700.97M-10.18720Positive News
NKTR
Nektar Therapeutics
4.8205 of 5 stars
$23.47
-5.2%
$84.17
+258.6%
+21.3%$307.20M$98.43M-2.45220Analyst Forecast
High Trading Volume
OMER
Omeros
3.2776 of 5 stars
$3.08
-3.8%
$18.00
+484.4%
-20.3%$187.50MN/A-1.16210Gap Down
ASMB
Assembly Biosciences
3.7657 of 5 stars
$18.56
+2.3%
$33.00
+77.8%
+40.5%$138.54M$28.52M-2.98100Trending News
Gap Up
CPIX
Cumberland Pharmaceuticals
0.5868 of 5 stars
$3.04
-3.5%
N/A+107.5%$47.13M$37.87M-12.1680
LLY
Eli Lilly and Company
4.9839 of 5 stars
$772.82
-1.0%
$1,011.61
+30.9%
-15.5%$739.87B$45.04B62.8847,000Trending News
Options Volume
JNJ
Johnson & Johnson
4.8405 of 5 stars
$155.23
-0.5%
$170.88
+10.1%
+6.0%$375.37B$88.82B17.27138,100Positive News
ABBV
AbbVie
4.9432 of 5 stars
$187.44
-1.0%
$211.29
+12.7%
+12.1%$334.34B$56.33B79.7655,000Trending News
Analyst Revision

Related Companies and Tools


This page (NASDAQ:SUPN) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners